Because back pain is a chronic condition for many patients, rheumatologists should increase their understanding of the common problems of the lumbar spine.
Study Supports Ultrasound Aortic Monitoring in Giant Cell Arteritis
A study identifies ultrasound as a safe, accessible & cost-effective alternative for longitudinal aortic surveillance in patients with GCA.
Study Finds Baricitinib Is Effective in Patients with Takayasu Arteritis
A small study shows baricitinib effectively treats refractory Takayasu arteritis & allows for glucocorticoid reduction with no serious adverse events recorded.
RA Research Presented at ACR Convergence 2025 in Focus
This synopsis of research into rheumatoid arthritis highlights key areas presented at ACR Convergence 2025, including strategies to delay or prevent RA, emerging mechanisms of action in RA treatment, and the growing role of AI in advancing RA research and clinical care.
Study: Inflammation Starts Earlier Than You Think
A recently published study shows that inflammatory disease begins well before synovitis is seen on exam; a better understanding of what’s brewing before the storm could lead to the development of preventive therapies for RA.
Prednisone or Methotrexate for Pulmonary Sarcoidosis?
The recently released PREDMETH study results indicate that methotrexate can be considered a real alternative to prednisone for patients with pulmonary sarcoidosis.
First ACR Guidance Statement for VEXAS Released
VEXAS is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. Given the variability in disease presentation & the limited number of studies to date, an international multidisciplinary panel of VEXAS experts was convened to provide guidance to healthcare providers on the condition’s management. We spoke to experts on the panel about the resulting guidance document.
Hydroxychloroquine Remains a Mainstay in Lupus Nephritis
New data: HCQ reduces risk of eGFR decline by 61–73% & slows kidney function loss. Early initiation is critical for renal health in lupus nephritis.
Obinutuzumab Aids Standard Therapy for Lupus Nephritis
Phase 3 REGENCY data: Obinutuzumab & standard therapy improve complete renal response rates in active lupus nephritis patients.
Research Reviews: AURORA 2, & Urinary Biomarkers
AURORA 2 Voclosporin, a novel calcineurin inhibitor (CNI), is associated with a favorable metabolic profile with regard to lipids and glucose, and a predictable pharmacokinetic profile, resulting in no need for the therapeutic drug monitoring required of other CNIs. AURORA 2, a double-blind, phase 3 study, evaluated the longterm safety, tolerability and efficacy of voclosporin…
- 1
- 2
- 3
- …
- 130
- Next Page »